Biology:Cambiogenplasmid

From HandWiki
Short description: Gene therapy medication
Cambiogenplasmid
Gene therapy
Target geneVEGF
VectorPlasmid
Clinical data
Trade namesNeovasculgen
Other namesPl-VEGF165
Routes of
administration
Intraneural injection
ATC code
Identifiers
CAS Number
ChemSpider
  • none

Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF).[1][2] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.[3][4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.

References

  1. "Vascular endothelial growth factor gene therapy - HSCI". Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800041695. 
  2. "Gene Therapy for PAD Approved". Drug Discovery and Development. 6 December 2011. http://www.dddmag.com/news/2011/12/gene-therapy-pad-approved. 
  3. "Neovasculogen listing in Eurolab". Eurolab. http://www.eurolab.ua/medicine/drugs/5411/. 
  4. "pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia". Journal of Cardiovascular Pharmacology and Therapeutics 20 (5): 473–82. September 2015. doi:10.1177/1074248415574336. PMID 25770117. 

See also

  • Therapeutic angiogenesis